Boston, MA – Moderna recently announced positive data from clinical trials on three new experimental vaccines, showcasing the company’s efforts to expand beyond its well-known Covid vaccine. These vaccines are now moving towards final stages of study, marking a significant step towards diversifying Moderna’s product portfolio.
The update comes at a crucial time for the company, given the decline in demand for Covid shots worldwide. With its Covid vaccine being the only product commercially available, Moderna has faced challenges, reflected in its stock shares falling by nearly 45% last year. In an effort to address this, the company is focusing on developing multiple products to meet market demands.
Moderna’s “Vaccines Day” event in Boston, which focuses on its vaccine portfolio, is where the company will discuss the new clinical trial data on the three vaccines. These vaccines target viruses such as norovirus, Epstein-Barr virus, and the virus causing shingles and chickenpox.
Furthermore, Moderna will provide updates on five other shots in late-stage clinical trials, including a combination vaccine for Covid and the flu, a vaccine against cytomegalovirus, and a jab against respiratory syncytial virus expected to receive regulatory approval in the U.S. in May. The company also revealed a stronger immune response from its “next-generation” Covid shot in late-stage trials.
In addition to vaccine developments, Moderna has entered into a funding agreement with Blackstone Life Sciences to advance its flu shot program. While the company is optimistic about its growing vaccine portfolio, executives anticipate a decrease in revenue in 2024 before a projected growth in 2025, aiming to break even in 2026.
The new vaccines targeting norovirus, Epstein-Barr virus, and varicella-zoster virus present significant opportunities for Moderna. These vaccines address unmet medical needs and offer potential solutions to prevalent health issues. As Moderna continues to advance its vaccine pipeline, the company remains focused on delivering innovative solutions to patients impacted by infectious diseases.